Company Overview of Progen Pharmaceuticals Limited
As of January 29, 2016, Progen Pharmaceuticals Limited was acquired by TBG Diagnostics Limited, in a reverse merger transaction. Progen Pharmaceuticals Limited, a biotechnology company, discovers, researches, and develops pharmaceutical therapeutics for the treatment of human diseases in Australia and the United States. The company focuses on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The company’s products in research and development stage include PG545, an anti-cancer compound in Phase Ia clinical trial; and PI-88, a heparanase inhibitor that is in Phase III clinical trial in post-resection liver cancer. It also provides contract services rela...
2806 Ipswich Road
Darra, QLD 4076
Key Executives for Progen Pharmaceuticals Limited
Progen Pharmaceuticals Limited does not have any Key Executives recorded.
Progen Pharmaceuticals Limited Key Developments
Progen Pharmaceuticals Limited will Change its Ticker to TDL from PGL
Jan 29 16
Effective February 02, 2016, Progen Pharmaceuticals Limited will change its Australian Securities Exchange stock ticker symbol to TDL from PGL.
Progen Pharmaceuticals Limited has Changed its Name to TBG Diagnostics Limited
Dec 14 15
On December 14, 2015, Progen Pharmaceuticals Limited changed its name to TBG Diagnostics Limited.
Progen Pharmaceuticals Limited Announces Changes to Board of Directors
Dec 8 15
Progen Pharmaceuticals Limited announced that Non-Executive Director, Dr. Christopher Harvey, who was due to stand for election as a Director at this year's Annual General Meeting on December 07, 2015, informed the Board that due to the overwhelming shareholder support for the new appointee directors, he decided he would not stand for election to the Board at the AGM. The Board of Directors appoints Dr. Stanley Chang, Eugene Cheng, and Emily Lee as elected directors to the Board of the company.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries